After four years running a start-up biotech company formed to combat viruses, David Perryman has returned to law practice.
He left intellectual property boutique Needle & Rosenberg in 2007, where he’d practiced for 16 years, to become the CEO of Zirus. He is rejoining his former colleagues as part of Ballard Spahr, the Philadelphia-based general practice firm that acquired Needle & Rosenberg three years ago.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
